[go: up one dir, main page]

RU2186109C2 - Полинуклеотидная противотуберкулезная вакцина - Google Patents

Полинуклеотидная противотуберкулезная вакцина Download PDF

Info

Publication number
RU2186109C2
RU2186109C2 RU97110087/13A RU97110087A RU2186109C2 RU 2186109 C2 RU2186109 C2 RU 2186109C2 RU 97110087/13 A RU97110087/13 A RU 97110087/13A RU 97110087 A RU97110087 A RU 97110087A RU 2186109 C2 RU2186109 C2 RU 2186109C2
Authority
RU
Russia
Prior art keywords
gene
dna
transcription
polynucleotide
protein
Prior art date
Application number
RU97110087/13A
Other languages
English (en)
Russian (ru)
Other versions
RU97110087A (ru
Inventor
Маргарет А. ЛИУ
Донна МОНТГОМЕРИ
Джеффри УЛМЕР
Жан КОНТЭН
Крис ЮИЖЕН
Original Assignee
Мерк Энд Ко., Инк.
Н.В. Иннодженетикс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк., Н.В. Иннодженетикс С.А. filed Critical Мерк Энд Ко., Инк.
Publication of RU97110087A publication Critical patent/RU97110087A/ru
Application granted granted Critical
Publication of RU2186109C2 publication Critical patent/RU2186109C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU97110087/13A 1994-11-14 1995-11-13 Полинуклеотидная противотуберкулезная вакцина RU2186109C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/338,992 US5736524A (en) 1994-11-14 1994-11-14 Polynucleotide tuberculosis vaccine
US338992 1994-11-14

Publications (2)

Publication Number Publication Date
RU97110087A RU97110087A (ru) 1999-06-27
RU2186109C2 true RU2186109C2 (ru) 2002-07-27

Family

ID=23326996

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97110087/13A RU2186109C2 (ru) 1994-11-14 1995-11-13 Полинуклеотидная противотуберкулезная вакцина

Country Status (23)

Country Link
US (2) US5736524A (fr)
EP (1) EP0792358B1 (fr)
JP (1) JP3881014B2 (fr)
KR (1) KR970707281A (fr)
CN (1) CN1171814A (fr)
AT (1) ATE296882T1 (fr)
AU (1) AU715067B2 (fr)
CZ (1) CZ289383B6 (fr)
DE (1) DE69534250T2 (fr)
DK (1) DK0792358T3 (fr)
ES (1) ES2242193T3 (fr)
FI (1) FI972034L (fr)
HU (1) HU222369B1 (fr)
IL (1) IL115883A0 (fr)
MX (1) MX9703606A (fr)
NO (1) NO972196L (fr)
NZ (1) NZ296477A (fr)
PL (1) PL184839B1 (fr)
PT (1) PT792358E (fr)
RU (1) RU2186109C2 (fr)
SK (1) SK283254B6 (fr)
WO (1) WO1996015241A2 (fr)
ZA (1) ZA959608B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242245C2 (ru) * 2003-01-10 2004-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственные микобактериальные частицы и противотуберкулезная вакцинная композиция на их основе
RU2262351C1 (ru) * 2003-12-26 2005-10-20 ООО "Фирма "БиоМедИнвест" Вакцинная композиция для профилактики и лечения туберкулезной инфекции и генетические конструкции для получения действующих компонентов этой композиции
RU2380375C2 (ru) * 2004-02-11 2010-01-27 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа Слитые белки карциноэмбрионального антигена
RU2539035C2 (ru) * 2011-01-13 2015-01-10 Амир Закиевич Максютов Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов

Families Citing this family (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US20070021364A1 (en) * 1995-12-13 2007-01-25 Hans Herweijer Methods for genetic immunization
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
JP2001500738A (ja) * 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
AU6148798A (en) * 1997-02-07 1998-08-26 Vanderbilt University Synthetic genes for recombinant mycobacterium proteins
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU3489499A (en) * 1998-04-14 1999-11-01 Merck & Co., Inc. Needleless administration of polynucleotide formulations
ATE445638T1 (de) * 1998-11-04 2009-10-15 Isis Innovation Tuberkulose diagnose test
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
ES2372592T3 (es) * 1999-04-08 2012-01-24 Intercell Usa, Inc. Formulación seca para la inmunización transcutánea.
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
CA2374610A1 (fr) * 1999-06-28 2001-01-04 Jordan J. N. Tang Memapsine recombinante catalytiquement active et procedes d'utilisation
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP2278021A3 (fr) * 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Vecteurs d'expression, systèmes de transfection et procédé d'utilisation correspondant
EP1230268B1 (fr) 1999-11-18 2009-10-14 Pharmexa Inc. Analogues heteroclites de classe i epitopes
EP1244687A4 (fr) * 1999-12-22 2005-06-15 Univ Ohio State Res Found PROCEDES DE PROTECTION CONTRE L'INFECTION LETALE PAR LE i BACILLUS ANTHRACIS /i
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
AU2001231245A1 (en) 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001062207A2 (fr) * 2000-02-23 2001-08-30 The Regents Of The University Of California Methode de traitement des maladies intestinales inflammatoires et d'autres formes d'inflammation gastro-intestinale
AU2001259291B2 (en) * 2000-04-28 2006-11-23 Aventis Pasteur Limited Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines
US6590087B1 (en) * 2000-05-25 2003-07-08 Johns Hopkins University whmD, an essential cell division gene from mycobacteria
WO2002004018A2 (fr) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Vaccin de mi-vie et procédé pour renforcer l'immunité anti-mycobactérienne
DE60138465D1 (de) 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
DE60135232D1 (de) 2000-08-28 2008-09-18 Agensys Inc Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
CA2425648A1 (fr) 2000-10-19 2002-04-19 Epimmune Inc. Peptides de liaison aux hla de classe i et ii et leurs utilisations
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
ATE398461T1 (de) * 2001-02-13 2008-07-15 Us Gov Sec Army Impstoffe zur transkutanen immunisierung gegen reisediarrhö
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
JP2004532213A (ja) * 2001-04-06 2004-10-21 ザ ユニヴァーシティ オヴ シカゴ Ｅｇｒ−１プロモーター活性の化学療法誘導
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US7013940B2 (en) * 2001-04-19 2006-03-21 Michelin Recherche Et Technique S.A. Device for attenuating cavity noise in a tire and wheel
CA2448097A1 (fr) 2001-05-22 2002-11-28 University Of Chicago Arn polymerase dependant de l'adn a brin unique de virion n4
US7604955B2 (en) * 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
ATE536100T1 (de) 2001-10-26 2011-12-15 Baylor College Medicine Zusammensetzung für die änderung der knocheneigenschaften bei einem probanden
CA2469310C (fr) 2001-12-11 2013-01-29 Advisys, Inc. Supplementation administree par plasmides pour le traitement de patients a maladie chronique
CA2474002A1 (fr) * 2002-01-18 2003-07-24 Bjarne Bogen Constructions d'adn d'anticorps bispecifique pour administration intramusculaire muscle
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (fr) 2002-02-01 2003-08-07 Ambion, Inc. Courts fragments d'arn interferant haute activite visant a reduire l'expression de genes cibles
WO2003063798A2 (fr) * 2002-02-01 2003-08-07 Cornell Research Foundation, Inc. Compositions et methodes de traitement de maladies infectieuses et inflammatoires
EP1478656B1 (fr) * 2002-02-01 2009-09-16 Life Technologies Corporation Compositions oligonucleotidiques presentant une efficacite amelioree
US20050267025A1 (en) * 2002-02-01 2005-12-01 Ho John L Compositions and methods for treatment of infectious and inflammatory diseases
US20050222060A1 (en) * 2002-03-15 2005-10-06 Bot Adrian L Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
EP2258712A3 (fr) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
US7078037B2 (en) * 2002-04-19 2006-07-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
WO2004041997A2 (fr) * 2002-05-01 2004-05-21 National Institutes Of Health Regimes d'immunotherapie chez des patients atteints du vih
EP2070949B1 (fr) 2002-06-10 2013-01-16 Vaccinex, Inc. Anticorps anti-C35 et leur application pour le traitement du cancer
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) * 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
CA2492160A1 (fr) * 2002-07-12 2004-01-22 The Johns Hopkins University Vaccins a la mesotheline et systemes de modele
AU2003304195B8 (en) 2002-07-15 2008-08-28 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20060247190A1 (en) * 2002-10-21 2006-11-02 Kathleen Beach Compositions and methods for treating human papillomavirus mediated disease
AU2002352976B2 (en) 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
EP1903056A3 (fr) 2002-12-10 2008-05-07 Idm Pharma, Inc. Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
EP2343315A3 (fr) 2003-02-10 2011-11-23 Agensys, Inc. Acide nucléique et protéine correspondante appelée 158P1D7 utile pour le traitement et la détection de cancer de la vessie et autres
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
CA2520181A1 (fr) * 2003-03-26 2004-10-14 Astral Inc. Motif d'arn selectionne destine a induire la mort cellulaire et/ou l'apoptose
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
WO2004098497A2 (fr) * 2003-04-28 2004-11-18 Genencor International, Inc. Epitopes cd4+ du papillomavirus
CN101090729B (zh) 2003-05-30 2014-07-23 艾更斯司股份有限公司 前列腺干细胞抗原(psca)变体及其序列
WO2004110482A1 (fr) * 2003-06-13 2004-12-23 Isis Innovation Limited Vaccins ameliores
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
CA2531698A1 (fr) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Methode de detection d'une interaction proteine-proteine
ATE557099T1 (de) * 2003-09-05 2012-05-15 Genencor Int Hpv cd8+ t-zell-epitope
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
WO2005090559A1 (fr) * 2004-03-18 2005-09-29 Fred Hutchinson Cancer Research Center Procedes et compositions impliquant des regions de promoteur s-ship
WO2005118864A2 (fr) 2004-05-28 2005-12-15 Agensys, Inc. Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)
WO2006017279A2 (fr) * 2004-07-12 2006-02-16 Board Of Regents, The University Of Texas System Procédés et compositions concernant l'identification des interactions protéine-protéine
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
EP2302053A1 (fr) 2004-11-12 2011-03-30 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
MX2007005256A (es) 2004-11-16 2008-03-11 Crucell Holland Bv Vacunas multivalentes que comprenden vectores virales recombinantes.
EA012182B1 (ru) * 2004-12-01 2009-08-28 ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН Электропорация микобактерии и сверхэкспрессия антигенов микобактерий
JP2008538894A (ja) * 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
EP2325305B1 (fr) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Vaccins à base de peptides pour cancers du poumon exprimant des polypeptides TTK, URLC10 ou KOC1
SI2095822T1 (sl) 2005-02-28 2013-12-31 Oncotherapy Science, Inc. Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
HUE027330T2 (en) 2005-07-27 2016-09-28 Oncotherapy Science Inc The TOM34 gene for colon cancer
JP2009505979A (ja) * 2005-08-10 2009-02-12 オクラホマ メディカル リサーチ ファンデーション アルツハイマー病の治療に使用するためのトランケート型メマプシン２
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
WO2007030668A2 (fr) * 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Traitement systemique de cancers metastasiques et/ou systemiquement dissemines a l'aide de poxvirus exprimant le gm-csf
US7919258B2 (en) * 2005-10-07 2011-04-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Rapid tuberculosis detection method
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2428801B1 (fr) * 2006-03-14 2014-05-07 Oregon Health and Science University Procédés pour détecter une infection de tuberculose à mycobactérie
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
CN100503824C (zh) * 2006-07-20 2009-06-24 武汉大学 抗结核杆菌感染的小分子核苷酸dna适配子及其制备方法
ATE543097T1 (de) 2006-07-27 2012-02-15 Univ Maryland Zellulärer rezeptor für antiproliferativen faktor
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
KR101454287B1 (ko) 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
JP2010507369A (ja) 2006-10-20 2010-03-11 アリゾナ ボード オブ リージェンツ フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティ 改変されたシアノバクテリア
EP2102239B1 (fr) 2006-11-30 2012-04-25 Research Development Foundation Bibliothèques d'immunoglobulines améliorées
TWI615403B (zh) 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
DK2155789T3 (da) 2007-05-01 2013-10-21 Res Dev Foundation Immunoglobulin-Fc-biblioteker
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
KR101661946B1 (ko) 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
EP3085707B1 (fr) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Peptides de liaison hla-dr et leurs utilisations
US9605035B2 (en) 2008-01-10 2017-03-28 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
WO2009092382A1 (fr) * 2008-01-23 2009-07-30 Rigshospitalet, Region Hovedstaden Classification d’individus souffrant de maladies cardiovasculaires selon des pronostics de survie tels que découverts en mesurant les concentrations du biomarqueur ykl-40
DK2245464T3 (en) 2008-01-25 2017-02-20 Multivir Inc P53 BIOMARKETS
SG10202103401QA (en) 2008-03-17 2021-05-28 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009117134A2 (fr) * 2008-03-21 2009-09-24 National Institutes Of Health Vaccins génétiques aérolisés et procédés d'utilisation
ATE513856T1 (de) * 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2009143167A2 (fr) 2008-05-19 2009-11-26 Advaxis Système de double distribution pour des antigènes hétérologues
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
AU2009256202B2 (en) 2008-06-04 2014-07-03 FUJIFILM Cellular Dynamics, Inc. Methods for the production of IPS cells using non-viral approach
BRPI0904621A2 (pt) * 2008-07-25 2015-06-30 Dept Of Biotechnology India Quimera recombinante de construção de dna
EP2331696A1 (fr) 2008-08-12 2011-06-15 Cellular Dynamics International, Inc. Procédés de production de cellules ips
US8912146B2 (en) 2008-08-18 2014-12-16 University Of Maryland, Baltimore Derivatives of APF and methods of use
US8512944B2 (en) 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
CN102333540B (zh) 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
EP2352747A1 (fr) * 2008-10-23 2011-08-10 Intervet International BV Lawsonia intracellularis vaccines
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
CN102317442B (zh) 2008-12-17 2014-08-13 斯克里普斯研究所 干细胞的产生和保持
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
CN105601725B (zh) 2009-03-18 2019-08-09 肿瘤疗法科学股份有限公司 Neil3肽及包含它的疫苗
WO2011005341A2 (fr) 2009-04-03 2011-01-13 University Of Chicago Compositions et méthodes associées aux variants de la protéine a (spa)
WO2010129347A2 (fr) 2009-04-28 2010-11-11 Vanderbilt University Compositions et procédés pour le traitement de troubles mettant en jeu une apoptose de cellules épithéliales
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
KR101811235B1 (ko) 2009-06-05 2017-12-21 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Ｔ 세포 및 조혈 세포의 재프로그래밍
US20110053803A1 (en) 2009-08-26 2011-03-03 Xin Ge Methods for creating antibody libraries
DK2477499T3 (en) 2009-09-14 2018-06-06 Sillajen Biotherapeutics Inc COMBINATION CANCER THERAPY WITH ONCOLYTIC VACCINIA VIRUS
CA2774636C (fr) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants diriges contre le vih-1 et utilisation associee
JP2013506682A (ja) * 2009-09-30 2013-02-28 セント ルイス ユニバーシティ 異種亜型インフルエンザｔ細胞応答を誘発するためのペプチド
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP6025255B2 (ja) 2009-12-10 2016-11-16 ターンストーン リミテッド パートナーシップ 腫瘍退縮性ラブドウイルス
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
WO2011100508A2 (fr) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Procédés et compositions liés à des fusions glycoprotéine-immunoglobuline
WO2011106298A1 (fr) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Mutations de braf conférant une résistance aux inhibiteurs de braf
WO2011106705A2 (fr) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protocoles de vaccination adn/protéine
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
MX344579B (es) 2010-03-11 2016-12-19 Oncotherapy Science Inc * Peptidos hjurp y vacunas que incluyen los mismos.
CA2800498C (fr) 2010-03-31 2021-11-16 The Scripps Research Institute Nouvelle programmation de cellules
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
WO2011126976A1 (fr) 2010-04-07 2011-10-13 Vanderbilt University Vaccins à réovirus et procédés d'utilisation associés
US8785385B2 (en) 2010-04-19 2014-07-22 Research Development Foundation RTEF-1 variants and uses thereof
EP3889254B8 (fr) 2010-06-09 2024-10-02 Dana-Farber Cancer Institute, Inc. Mutation de mek1 conférant une résistance à des inhibiteurs de raf et de mek
EP2580320B1 (fr) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogrammation de cellules pour leur conférer un nouveau destin
WO2011159797A2 (fr) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Compendium de modèles de cellules souches préfabriqués pour l'interrogation d'une réponse biologique
AU2011267849B2 (en) 2010-06-15 2015-02-05 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
NZ704322A (en) 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012006440A2 (fr) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Production de cellules endothéliales par programmation
WO2012018933A2 (fr) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogrammation des lymphocytes b immortalisés
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US9084746B2 (en) 2010-09-22 2015-07-21 The Regents Of The University Of Colorado, A Body Corporate Therapeutic applications of SMAD7
WO2012044979A2 (fr) 2010-10-01 2012-04-05 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Manipulation de la fonction de cellules souches par des isoformes p53
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
KR20200113286A (ko) 2010-12-22 2020-10-06 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
AU2012204467B2 (en) 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2474617A1 (fr) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR pour traiter une nouvelle angiogenèse
WO2012109133A1 (fr) 2011-02-07 2012-08-16 Research Development Foundation Polypeptides fc modifiés d'immunoglobuline
CA2826386C (fr) 2011-02-08 2020-04-28 Cellular Dynamics International, Inc. Production de precurseurs hematopoietiques obtenus par programmation
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
US9085631B2 (en) 2011-04-08 2015-07-21 Nov Vac APS Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
WO2012167382A1 (fr) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions et procédés pour le traitement du glioblastome
US20130040302A1 (en) 2011-07-11 2013-02-14 Thomas J. Burke Methods for cell reprogramming and genome engineering
US9725490B2 (en) 2011-07-29 2017-08-08 Tokushima University ERAP1-derived peptide and use thereof
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
WO2013026015A1 (fr) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Pièges de ligand de muc1 pour l'utilisation dans le traitement de cancers
JP2013046596A (ja) * 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd 新規な複合体、それを含有する医薬及び癌の治療方法
WO2013053899A1 (fr) 2011-10-12 2013-04-18 Moeller Niels Iversen Peptides dérivés de campylobacter jejuni et leur utilisation en vaccination
US9427461B2 (en) 2011-10-28 2016-08-30 Oncotherapy Science, Inc. TOPK peptides and vaccines including the same
US10174314B2 (en) 2011-12-22 2019-01-08 Interna Technologies B.V. MiRNA for treating head and neck cancer
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
JP6255594B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
WO2014010231A1 (fr) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Peptides épitopes du kif20a pour cellules th1 et vaccins les contenant
PL2895600T3 (pl) 2012-09-11 2020-10-05 Oncotherapy Science, Inc. Peptydy UBE2T i szczepionki je zawierające
CA2887825A1 (fr) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Anticorps avec des domaines fc d'igg modifies
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
WO2014116721A1 (fr) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Vecteur geminiviral pour l'expression du rituximab
BR112015019950B1 (pt) 2013-02-20 2023-02-14 Regeneron Pharmaceuticals, Inc Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro
MX377363B (es) 2013-02-21 2025-03-10 Turnstone Lp Composición de vacuna.
AU2014218807A1 (en) 2013-02-22 2015-09-03 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2014134144A1 (fr) 2013-02-28 2014-09-04 The General Hospital Corporation Compositions de profilage de miarn et procédés d'utilisation
CA2904329C (fr) 2013-03-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Produits therapeutiques ptd-smad7
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
EP2968506B1 (fr) * 2013-03-15 2019-07-31 Université de Genève Vaccins anti-mycobactériens
WO2014153636A1 (fr) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Méthode d'amélioration de l'efficacité d'un vaccin à base de survivine pour le traitement du cancer
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
AU2014317861B2 (en) 2013-09-09 2019-11-28 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
EP3065775B1 (fr) 2013-11-08 2020-09-30 The Board of Regents of the University of Texas System Anticorps vh4 dirigés contre les astrocytes et les neurones de la matière grise
EP4227685A3 (fr) 2013-12-03 2024-02-28 Evaxion Biotech A/S Proteines et acides nucleiques utiles dans des vaccins ciblant staphylococcus aureus
CN106132992B (zh) 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
US10214741B2 (en) 2014-02-14 2019-02-26 University Of Utah Research Foundation Methods and compositions for inhibiting retinopathy of prematurity
US20170037091A1 (en) 2014-02-25 2017-02-09 Research Development Foundation Sty peptides for inhibition of angiogenesis
EP4647498A2 (fr) 2014-03-04 2025-11-12 Fate Therapeutics, Inc. Procédés de reprogrammation améliorés et plateformes de culture cellulaire
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
KR20170040315A (ko) 2014-08-04 2017-04-12 온코세라피 사이언스 가부시키가이샤 Cdca1-유래 펩티드 및 이를 포함하는 백신
KR20220155610A (ko) 2014-08-04 2022-11-23 온코세라피 사이언스 가부시키가이샤 Koc1-유래 펩티드 및 이를 포함하는 백신
AU2015300260B2 (en) 2014-08-04 2020-01-02 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
US20180363070A9 (en) 2014-08-12 2018-12-20 Univ Wayne State Systems and methods to detect stem cell stress and uses thereof
EP3218002B1 (fr) 2014-11-13 2020-08-19 Evaxion Biotech ApS Peptides dérivés d'acinetobacter baumannii et leur utilisation en vaccination
EP3242883A4 (fr) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Mimétiques de lipide a, procédés de préparation, et leurs utilisations
EP4279080A3 (fr) 2015-01-12 2024-02-21 Evaxion Biotech A/S Traitement et prophylaxie d'une infection k. pneumoniae
WO2016120697A1 (fr) 2015-01-28 2016-08-04 Sabic Global Technologies B.V. Procédés et compositions pour une production à haut rendement de biocarburant et/ou de biomasse
EP3256490A1 (fr) 2015-02-09 2017-12-20 Research Development Foundation Polypeptides ayant un domaine fc d'immunoglobuline modifié manifestant une activation du complément améliorée
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
US20180346520A1 (en) 2015-05-13 2018-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (fr) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension de durée de vie réplicative dans des maladies de vieillissement prématuré à l'aide d'isoformes p53
EP4116316A1 (fr) 2015-07-04 2023-01-11 Evaxion Biotech A/S Protéines et acides nucléiques utiles dans des vaccins ciblant pseudomonas aeruginosa
WO2017040380A2 (fr) 2015-08-28 2017-03-09 Research Development Foundation Variants de fc d'anticorps modifiés
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
CN108137652B (zh) 2015-10-08 2021-08-03 肿瘤疗法科学股份有限公司 Foxm1衍生的肽和包含它们的疫苗
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
CN108431211A (zh) 2015-10-20 2018-08-21 富士胶片细胞动力公司 通过遗传编程的多谱系造血前体细胞产生
TWI812584B (zh) 2015-10-30 2023-08-21 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
ES2892972T3 (es) 2015-11-02 2022-02-07 Univ Texas Métodos de activación de CD40 y bloqueo de punto de control inmunitario
EP3371221A2 (fr) 2015-11-07 2018-09-12 MultiVir Inc. Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer
HUE067793T2 (hu) 2015-11-09 2024-11-28 Childrens Hospital Philadelphia Glipikán 2 mint rákmarker és terápiás célpont
US10946084B2 (en) 2016-02-22 2021-03-16 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
CA3019635A1 (fr) 2016-03-31 2017-10-05 Baylor Research Institute Proteine 8 de type angiopoietine (angptl8)
WO2017216384A1 (fr) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination ciblant ichthyophthirius multifiliis
CN109843321A (zh) * 2016-06-22 2019-06-04 国际艾滋病疫苗行动组织公司 作为结核病疫苗的重组巨细胞病毒载体
WO2017220787A1 (fr) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccin contre l'infection provoquée par aeromonas salmonicida
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
EP3487872A1 (fr) 2016-07-22 2019-05-29 Evaxion Biotech ApS Protéines chimériques pour induire une immunité vis-à-vis d'une infection à s. aureus
WO2018035429A1 (fr) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides qui inhibent l'activation de syndécane-1 de vla-4 et de l'igf-1r
CA3039136A1 (fr) 2016-09-02 2018-03-08 The Regents Of The University Of California Methodes et compositions impliquant des fragments variables a chaine unique (scfv) de liaison au recepteur alpha de l'interleukine-6
CN110023491B (zh) 2016-10-05 2024-03-08 富士胶片细胞动力公司 多能干细胞定向分化为hla纯合免疫细胞的方法
WO2018067826A1 (fr) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Génération de lignées matures à partir de cellules souches pluripotentes induites avec une interruption mecp2
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
US11718648B2 (en) 2017-01-05 2023-08-08 Evaxion Biotech A/S Vaccines targeting Pseudomonas aeruginosa
CA3058779A1 (fr) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Lymphocytes effecteurs immunitaires specifiques de l'antigene
US20220185849A1 (en) 2017-05-19 2022-06-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019099493A1 (fr) 2017-11-14 2019-05-23 Henry Ford Health System Compositions destinées à être utilisées dans le traitement et la prévention de troubles cardiovasculaires résultant d'une lésion cérébrovasculaire
US20200385758A1 (en) 2018-01-05 2020-12-10 Ottawa Hospital Research Institute Modified vaccinia vectors
WO2019145399A1 (fr) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccins pour la prophylaxie d'infections par s. aureus
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
EP3775214A2 (fr) 2018-03-30 2021-02-17 University of Geneva Constructions d'expression de micro arn et leurs utilisations
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN113164556A (zh) 2018-08-30 2021-07-23 特纳亚治疗股份有限公司 用心肌蛋白和ascl1进行的心脏细胞重编程
US20220000932A1 (en) 2018-09-28 2022-01-06 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
US20220111031A1 (en) 2018-10-22 2022-04-14 Evaxion Biotech Aps Vaccines targeting M. catharrhalis
WO2020086927A1 (fr) 2018-10-26 2020-04-30 Saint Louis University Peptides pour induire des réponses hétérosubtypiques de lymphocytes t de la grippe
EP3889264A4 (fr) 2018-11-30 2022-10-12 Tokushima University Agent thérapeutique pour le traitement du cancer du sein comprenant un peptide inhibiteur d'interaction big3-phb2 dérivé de phb2
WO2020171889A1 (fr) 2019-02-19 2020-08-27 University Of Rochester Blocage de l'accumulation des lipides ou de l'inflammation dans la maladie oculaire thyroïdienne
WO2020174044A1 (fr) 2019-02-27 2020-09-03 Evaxion Biotech Aps Vaccins ciblant h. influenzae
SG10201905939WA (en) 2019-06-26 2021-01-28 Cell Mogrify Australia Pty Ltd Cell culture methods and compositions
WO2021007515A1 (fr) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Reprogrammation de cellules cardiaques avec des microarn et d'autres facteurs
WO2021016062A1 (fr) 2019-07-19 2021-01-28 The Children's Hospital Of Philadelphia Récepteurs antigéniques chimériques contenant des domaines de liaison au glypicane 2
US20210147525A1 (en) 2019-10-18 2021-05-20 The Regents Of The University Of California Methods and compositions for treating pathogenic blood vessel disorders
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
EP4087593A1 (fr) 2020-01-06 2022-11-16 Evaxion Biotech A/S Vaccins ciblant neisseria gonorrhoeae
WO2021178246A1 (fr) 2020-03-02 2021-09-10 Tenaya Therapeutics, Inc. Régulation de vecteur génique au moyen de micro-arn exprimés par des cardiomyocytes
US20230211023A1 (en) 2020-03-25 2023-07-06 Erasmus University Medical Center Rotterdam Reporter system for radionuclide imaging
AU2021278356A1 (en) 2020-05-27 2022-11-03 Antion Biosciences Sa Adapter molecules to re-direct CAR T cells to an antigen of interest
IL298254A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
CN116033912A (zh) 2020-05-29 2023-04-28 富士胶片细胞动力公司 视网膜色素上皮和感光器双细胞聚集物及其使用方法
WO2022053130A1 (fr) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 pour le traitement des cancers induits par v-src, c-src-tyrosine kinase
WO2022098845A1 (fr) 2020-11-05 2022-05-12 Board Of Regents, The University Of Texas System Antigènes egfr ciblant les récepteurs de lymphocytes t génétiquement modifiés et leurs méthodes d'utilisation
CA3202849A1 (fr) 2021-02-09 2022-08-18 University Of Houston System Virus oncolytique pour l'administration systemique et les activites anti-tumorales ameliorees
EP4294445A1 (fr) 2021-02-19 2023-12-27 Pfizer Inc. Procédés de protection de l'arn
CA3216719A1 (fr) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Procedes de generation de cellules endotheliales corneennes matures
KR20240005887A (ko) 2021-05-07 2024-01-12 아스텔라스 인스티튜트 포 리제너러티브 메디슨 성숙한 간세포를 발생시키는 방법
KR20240011831A (ko) 2021-05-26 2024-01-26 후지필름 셀룰러 다이내믹스, 인코포레이티드 만능 줄기 세포에서 유전자의 신속한 사일런싱을 방지하기 위한 방법
WO2023280807A1 (fr) 2021-07-05 2023-01-12 Evaxion Biotech A/S Vaccins ciblant neisseria gonorrhoeae
EP4436595A1 (fr) 2021-11-22 2024-10-02 Pfizer Inc. Réduction du risque de mimétisme antigènique dans des médicaments immunogènes
WO2023144779A1 (fr) 2022-01-28 2023-08-03 Pfizer Inc. Variants d'antigène de coronavirus
WO2023178191A1 (fr) 2022-03-16 2023-09-21 University Of Houston System Système d'administration de gène hsv persistant
GB202205265D0 (en) 2022-04-11 2022-05-25 Mogrify Ltd Cell conversion
JP2025516318A (ja) 2022-05-04 2025-05-27 エヴァクシオン・バイオテック・アクティエセルスカブ ブドウ球菌タンパク質変異体およびトランケート
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
AU2023283773A1 (en) 2022-06-10 2024-12-19 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
JP2025525436A (ja) 2022-06-29 2025-08-05 フジフィルム ホールディングス アメリカ コーポレイション Ｉｐｓｃ由来アストロサイト及びその使用方法
WO2024130212A1 (fr) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Virus de la vaccine recombinant codant pour des un ou plusieurs inhibiteurs de cellules tueuses naturelles et de lymphocytes t
WO2024186630A1 (fr) 2023-03-03 2024-09-12 Henry Ford Health System Utilisation de vésicules extracellulaires pour le traitement du cancer
GB202306619D0 (en) 2023-05-04 2023-06-21 Antion Biosciences Sa Cell
WO2025050009A2 (fr) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification de cibles pour une immunothérapie dans un mélanome à l'aide de néo-antigènes dérivés d'épissage
GB202402745D0 (en) 2024-02-27 2024-04-10 Antion Biosciences Sa Cell

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
JP3250802B2 (ja) * 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
DD295869A5 (de) * 1989-09-19 1991-11-14 �K�K@������������@�K�Kk�� Rekombinante polypeptide und peptide, diese codierende nucleinsaeuren und verwendung dieser polypeptide und peptide in der diagnose von tuberkulose
EP0499003A1 (fr) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides et peptides, en particulier polypeptides et peptides recombinants, acides nucléiques les encodantes, et leur utilisation pour le diagnostic de la tuberculose
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0620277A1 (fr) * 1993-03-18 1994-10-19 Merck & Co. Inc. Acides nucléiques comme produits pharmaceutiques
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1997000067A1 (fr) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Sequences d'adn isolees de mycobacterium tuberculosis codant des peptides immunostimulateurs
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEAN CONTENT and an. The Genes Coding for the Antigen 85 Complexes of Mycobacterium tuberculosis and Micobacterium bovis BCG Are Members of a Gene Family. "Infection and Immunity", v.59, N 9, sept.1991, р.3205-3212. LUK DE WIT and an. Nucleotide sequence of the 32 kDa-protein gene (antigen 85 A) of Micobacterium bovis BCG. "Nucleic Acids Research", v.18, N 13, 30.05.1990, р.3995. MARTINE BORRMANS and an. Cloning, Sequence Determination, and Expression of a 32 kDa- protein Gene of Mycobacterium tuberculosis. "Infection and Immunity", v.57, N 10, Okt.1989, р.3123-3130. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242245C2 (ru) * 2003-01-10 2004-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственные микобактериальные частицы и противотуберкулезная вакцинная композиция на их основе
RU2262351C1 (ru) * 2003-12-26 2005-10-20 ООО "Фирма "БиоМедИнвест" Вакцинная композиция для профилактики и лечения туберкулезной инфекции и генетические конструкции для получения действующих компонентов этой композиции
RU2380375C2 (ru) * 2004-02-11 2010-01-27 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа Слитые белки карциноэмбрионального антигена
RU2539035C2 (ru) * 2011-01-13 2015-01-10 Амир Закиевич Максютов Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов

Also Published As

Publication number Publication date
KR970707281A (ko) 1997-12-01
DK0792358T3 (da) 2005-08-29
DE69534250T2 (de) 2006-05-04
DE69534250D1 (de) 2005-07-07
NO972196L (no) 1997-07-11
NZ296477A (en) 1999-04-29
HU222369B1 (hu) 2003-06-28
JP3881014B2 (ja) 2007-02-14
WO1996015241A2 (fr) 1996-05-23
MX9703606A (es) 1998-07-31
HUT77028A (hu) 1998-03-02
AU715067B2 (en) 2000-01-13
FI972034A7 (fi) 1997-07-11
JPH10508753A (ja) 1998-09-02
NO972196D0 (no) 1997-05-13
AU4110296A (en) 1996-06-06
ZA959608B (en) 1996-05-29
EP0792358B1 (fr) 2005-06-01
CZ145197A3 (en) 1997-10-15
PT792358E (pt) 2005-09-30
US5736524A (en) 1998-04-07
US20020032162A1 (en) 2002-03-14
SK59797A3 (en) 1998-01-14
ES2242193T3 (es) 2005-11-01
CZ289383B6 (cs) 2002-01-16
PL184839B1 (pl) 2002-12-31
US6384018B1 (en) 2002-05-07
CN1171814A (zh) 1998-01-28
WO1996015241A3 (fr) 1996-11-07
PL320091A1 (en) 1997-09-15
IL115883A0 (en) 1996-01-31
ATE296882T1 (de) 2005-06-15
EP0792358A2 (fr) 1997-09-03
FI972034L (fi) 1997-07-11
FI972034A0 (fi) 1997-05-13
SK283254B6 (sk) 2003-04-01

Similar Documents

Publication Publication Date Title
RU2186109C2 (ru) Полинуклеотидная противотуберкулезная вакцина
US7097965B2 (en) Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
JP4764585B2 (ja) タンパク質抗原およびペプチド抗原の免疫原性を増強するためのｆｃ融合タンパク質
ES2342778T3 (es) Polipeptidos para la induccion de una respuesta inmunitaria de proteccion contra staphylococcus aureus.
BR112021005079A2 (pt) vacina contra o vírus da peste suína africana
US7094767B2 (en) Polynucleotide herpes virus vaccine
JP4653934B2 (ja) バクテリオファージによって仲介される免疫化方法
US20050256070A1 (en) Adjuvant
KR20060123138A (ko) 방법
AU708460B2 (en) A polynucleotide herpes virus vaccine
US20050226846A1 (en) Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression
CA2846486C (fr) Nouveau vaccin a adn dirige contre clostridium difficile
KR20040045391A (ko) 핵산 어쥬번트
US20050266024A1 (en) Adjuvant
US20020086837A1 (en) Acne vaccine
US11179458B2 (en) Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus
CA2205175C (fr) Vaccin polynucleotidique contre la tuberculose
US20040082530A1 (en) Nucleic acid immunization
JP2025534692A (ja) 再発性呼吸器乳頭腫症用のワクチン及びその使用方法
JP2003528816A (ja) ヒトおよび動物の病原体のゲノム由来の構築物に基づいたｄｎａワクチン
Deshpande Host-pathogen interaction in bovine respiratory disease:(1) DNA immunization against bovine herpesvirus-1.(2) Role of CD18 in Mannheimia haemolytica leukotoxin-induced cytolysis of bovine leukocytes
HK1228285B (zh) Mers-cov疫苗
HUP0001347A2 (hu) Szintetikus HIV gag gének

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20091114